Ceftazidime–avibactam is a combination of ceftazidime, which is a third-generation cephalosporin, and avibactam, which is a next generation non-beta-lactam beta-lactamase inhibitor. Ceftazidime binds to a variety of bacterial penicillin-binding proteins, and avibactam inactivates a range of carbapenemase enzymes. Ceftazidime–avibactam is administered as an intravenous infusion over 2 hours, and given every 8 hours. Dosage adjustment is needed for people with renal impairment.
Ceftazidime–avibactam (Zavicefta, Pfizer) is indicated in:
adults and children aged 3 months and older for treating complicated intra-abdominal infection, complicated urinary tract infection including pyelonephritis, and hospital-acquired pneumonia including ventilator-associated pneumonia
adults with bacteraemia in association with, or that is suspected to be associated with, any of the infections listed above
adults and children aged 3 months and older with infections caused by aerobic gram-negative organisms, when there are few treatment options.
The dosage schedule is available in ceftazidime–avibactam's summary of product characteristics.